cas 2689-69-2|| where to buy Methyl 3-oxotetrahydrothiophene-2-carboxylate

Produktname:Methyl 3-oxotetrahydrothiophene-2-carboxylate

IUPAC Name:methyl 3-oxothiolane-2-carboxylate

Packungseinheit	Verfügbarer Vorrat	Preis($)
CM199155-1g	in stock	ƿƿ
CM199155-5g	in stock	ȯŪƥ
CM199155-10g	in stock	ƃŞƛ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2689-69-2 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:2689-69-2; Molekulare Formel:C6H8O3S; Schmelzpunkt:-; SMILES-Code:COC(=O)C1SCCC1=O; Dichte:

: Katalognummer:CM199155; Molekulargewicht:160.19; Siedepunkt:248.4°C at 760 mmHg; Mdl-Nr.:MFCD00156156; Lagerung:Keep in dark place, store at 2-8°C.

: Tetrahydrothiophenes; Tetrahydrothiophene is a sulfur-containing saturated heterocyclic compound obtained by catalytic hydrogenation of thiophene. After thiophene is reduced to tetrahydrothiophene, it no longer has a conjugated system and aromaticity. Therefore, tetrahydrothiophene shows the properties of general thioethers. Easily oxidized to sulfoxides and sulfones. Tetrahydrothiophene can be used as a raw material for the production of pharmaceuticals, pesticides and photochemicals.

: Nerandomilast; Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study.
Nerandomilast (BI 1015550) is an investigational oral, preferential inhibitor of phosphodiesterase 4B (PDE4B) that is being studied as a potential treatment for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). This compound is an investigational agent and has not been approved for use. Nerandomilast was granted FDA Breakthrough Therapy Designation for the treatment of IPF in February 2022.